Female genital tract immunity: Distinct immunological challenges for vaccine development

Journal of Reproductive Immunology

Volumn 93, Issue 1, 2012, Pages 1-8

  Naz, Rajesh K ^a  

^a WEST VIRGINIA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Contraceptive vaccines; Female genital tract; Infertility; Mucosal immunity; Sexually transmitted diseases; Vaccines

Indexed keywords

IMMUNOGLOBULIN A; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M;

ADAPTIVE IMMUNITY; DRUG ADMINISTRATION ROUTE; EPITHELIUM CELL; FEMALE GENITAL SYSTEM; GASTROINTESTINAL TRACT; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; INNATE IMMUNITY; LYMPHATIC SYSTEM; LYMPHOID TISSUE; MENSTRUAL CYCLE; METHODOLOGY; NASOPHARYNX; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; VACCINATION;

ADAPTIVE IMMUNITY; ANIMALS; CLINICAL PROTOCOLS; FEMALE; FOLLICULAR PHASE; GENITALIA, FEMALE; HIV INFECTIONS; HUMANS; MICE; MUCOUS MEMBRANE; SEXUALLY TRANSMITTED DISEASES; UTERINE CERVICAL NEOPLASMS; VACCINATION; VACCINES;

EID: 84855942574     PISSN: 01650378     EISSN: 18727603     Source Type: Journal    
DOI: 10.1016/j.jri.2011.09.005     Document Type: Review

References (96)

1. Anderson D.J. The importance of mucosal immunology to problems in human reproduction. J. Reprod. Immunol. 1996, 31:3-19.
2. Baba T.W., Liska V., Hofmann-Lehmann R., Vlasak J., Xu W., Ayehunie S., Cavacini L.A., Posner M.R., Katinger H., Stiegler G., Bernacky B.J., Rizvi T.A., Schmidt R., Hill L.R., Keeling M.E., Lu Y., Wright J.E., Chou T.C., Ruprecht R.M. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nat. Med. 2000, 6:200-206.
3. Batra S.K., Jain M., Wittel U.A., Chauhan S.C., Colcher D. Pharmacokinetics and biodistribution of genetically engineered antibodies. Curr. Opin. Biotechnol. 2002, 13:603-608.
4. Black C.A., Rohan L.C., Cost M., Watkins S.C., Draviam R., Alber S., Edwards R.P. Vaginal mucosa serves as an inductive site for tolerance. J. Immunol. 2000, 165:5077-5083.
5. Brekke O.H., Sandlie I. Therapeutic antibodies for human diseases at the dawn of the twenty-first century. Nat. Rev. Drug Discov. 2003, 2:52-62.
6. Buonaguro L., Devito C., Tornesello M.L., Schroder U., Wahren B., Jinkula J., Buonaguro F.M. DNA-VLP prime-boost intra-nasal immunization induces cellular and humoral anti-HIV-1 systemic and mucosal immunity with cross-clade neutralizing activity. Vaccine 2007, 25:5968-5977.
7. Del Campo J., Zayas C., Romeu B., Acevedo R., Gonzalez E., Bracho G., Cuello M., Cabrera O., Balboa J., Lastre M. Mucosal immunization using proteoliposome and cochleate structures from neisseria meningitides serogroup B induce mucosal and systemic responses. Methods 2009, 49:301-308.
8. Ebensen T., Schulze K., Riese P., Morr M., Guzman C.A. Bacterial second messenger cdiGMP exhibits promising activity as a mucosal adjuvant. Clin. Vaccine Immunol. 2007, 14:952-958.
9. Echchannaoui H., Bianchi M., Baud D., Bobst M., Stehle J.C., Nardelli-Haefliger D. Intravaginal immunization of mice with recombinant salmonella enteric serovar typhimurium expressing human papillomavirus type 16 antigens as a potential route of vaccination against cervical cancer. Infect. Immun. 2008, 76:1940-1951.
10. Edwards J.N.T., Morris H.B. Langerhan's cells and lymphocyte subsets in the female genital tract. Br. J. Obstet. Gynaecol. 1985, 92:974-982.
11. Ferko B., Kittel C., Romanova J., Sereinig S., Katinger H., Egorov A. Live attenuated influenza virus expressing human interleukin-2 reveals increased immunogenic potential in young and aged hosts. J. Virol. 2006, 80:11621-11627.
12. Ferreira D.M., Darrieux M., Silva D.A., Leite L.C.C., Ferreira J.M.C., Ho P.L., Miyaji E.N., Oliveira M.L.S. Characterization of protective mucosal and systemic immune responses elicited by pneumococcal surface protein PspA and PspC nasal vaccines against a respiratory pneumococcal challenge in mice. Clin. Vaccine Immunol. 2009, 16:636-645.
13. Fu Y., He J., Zheng X., Wang X., Xie C., Shi C., Zhang M., Tang Q., Wei W., Qu J., Hong T. Intranasal vaccination with a helper-dependent adenoviral vector enhances transgene-specific immune responses in BALB/c mice. Biochem. Biophys. Res. Commun. 2010, 391:857-861.
14. Gai W., Zhang Y., Zhou D., Chen Y., Yang J., Yan H. PIKA provides an adjuvant effect to induce strong mucosal and systemic humoral immunity against SARS-CoV. Virol. Sin. 2011, 26:81-94.
15. Garulli B., Meola M., Stillitano M.G., Kawaoka Y., Castrucci M.R. Efficient vagina-to-lower respiratory tract immune trafficking in a model of influenza A virus infection. Virology 2007, 361:274-282.
16. Given A.L., White H.D., Stern J.E., Colby E., Gosselin E.J., Euyre P.M., Wira C.R. Flow cytometric analysis of leukocytes in the human female reproductive tract: comparison of fallopian tube, uterus, cervix, and vagina. Am. J. Reprod. Immunol. 1997, 38:350-359.
17. Gorfu G., Rivera-Nieves J., Ley K. Role of beta7 integrins in intestinal lymphocyte homing and retention. Curr. Mol. Med. 2009, 9:836-850.
18. Gupta P.N., Vyas S.P. Investigation of lectinized liposomes as M-cell targeted carrier-adjuvant for mucosal immunization. Colloids Surf. B: Biointerfaces 2011, 82:118-125.
19. Henshaw S.K. Unintended pregnancy in the United States. Fam. Plann. Perspect. 1998, 30:24-29.
20. Holliger P., Hudson P. Engineered antibody fragments and the rise of single domains. Nat. Biotechnol. 2005, 23:1126-1136.
21. Horne A.W., Stock S.J., King A.E. Innate immunity and disorders of the female reproductive tract. Reproduction 2008, 135:739-749.
22. Jaganathan K.S., Vyas S.P. Strong systemic and mucosal immune responses to surface-modified PLGA microspheres containing recombinant hepatitis B antigen administered intranasally. Vaccine 2006, 24:4201-4211.
23. Jain A.K., Goyal A.K., Mishra N., Vaidya B., Mangal S., Vyas S.P. PEG-PLA-PEG block copolymeric nanoparticles for oral immunization hepatitis B. Int. J. Pharm. 2010, 387:253-262.
24. Johansson E.L., Rudin A., Wassen L., Holmgren J. Distribution of lymphocytes and adhesion molecules in human cervix and vagina. Immunology 1999, 96:272-277.
25. Judlin P.G., Thiebaugeorges O. Pelvic inflammatory diseases. Gynecol. Obstet. Fertil. 2009, 37:172-182.
26. Kaushic C. HIV-1 infection in the female reproductive tract: role of interactions between HIV-1 and genital epithelial cells. Am. J. Reprod. Immunol. 2011, 65:253-260.
27. Kayamuro H., Yoshioka Y., Abe Y., Katayama K., Yoshida T., Yamashita K., Yoshikawa T., Hiroi T., Itoh N., Kawai Y., Mayumi T., Kamada H., Tsunoda S., Tsutsumi Y. TNF superfamily member, TL1A, is a potential mucosal vaccine adjuvant. Biochem. Biophys. Res. Commun. 2009, 384:296-300.
28. Keller M.J., Guzman E., Hazrati E., Kasowitz A., Cheshenko N., Wallenstein S., Cole A.L., Cole A.M., Profy A.T., Wira C.R., Hogarty K., Herold B.C. PRO 2000 elicits a decline in genital tract immune mediators without compromising intrinsic antimicrobial activity. AIDS 2007, 21:467-476.
29. Kozlowski P.A., Cu-Uvin S., Neutra M.R., Flanigan T.P. Comparison of the oral, rectal, and vaginal immunization routes for induction of antibodies in rectal and genital tract secretions of women. Infect. Immun. 1997, 65:1387-1394.
30. Kozlowski P.A., Cu-Uvin S., Neutra M.R., Flanigan T.P. Mucosal vaccination strategies for women. J. Infect. Dis. 1999, 179:493-498.
31. Kozlowski P.A., Williams S.B., Lynch R.M., Flanigan T.P., Patterson R.R., Cu-Uvin S., Neutra M.R. Differential induction of mucosal and systemic antibody responses in women after nasal, rectal, or vaginal immunization: influence of the menstrual cycle. J. Immunol. 2002, 169:566-574.
32. Krause W., Naz R.K. Immune Infertility 2009, 1-236. Springer Verlag, Berlin, Germany. W. Krause, R.K. Naz (Eds.).
33. Kuo-Haller P., Cu Y., Blum J., Appleton J.A., Saltzman W.M. Vaccine delivery by polymeric vehicles in the mouse reproductive tract induces sustained local and systemic immunity. Mol. Pharm. 2010, 7:1585-1595.
34. Kutteh W.H., Prince S.J., Hammond K.R., Kutteh C.C., Mestecky J. Variations in immunoglobulins and IgA subclasses of human uterine cervical secretions around the time of ovulation. Clin. Exp. Immunol. 1996, 104:538-542.
35. Kutteh W.H., Moldovenanu Z., Mestecky J. Mucosal immunity in the female reproductive tract: correlation of immunoglobulins, cytokines, and reproductive hormones in human cervical mucus around the time of ovulation. AIDS Res. Hum. Retroviruses 1998, 14:S51-S55.
36. Kwant-Mitchell A., Ashkar A.A., Rosenthal K.L. Mucosal innate and adaptive immune responses against herpes simplex virus type 2 in a humanized mouse model. J. Virol. 2009, 83:10664-10676.
37. Lee T.Y., Kim Y.H., Lee K.S., Kim J.K., Lee I.L., Yang J.M., Sung M.H., Park J.S., Poo H. Human papillomavirus type 16 E6-specific antitumor immunity is induced by oral administration of HPV16 E6-expressing lactobacillus casei in C57BL/6 mice. Cancer Immunol. Immunother. 2010, 59:1727-1737.
38. Lindqvist M., Persson J., Thorn K., Harandi A.M. The mucosal adjuvant effect of α-galactosylceramide for induction of protective immunity to sexually transmitted viral infection. J. Immunol. 2009, 182:6435-6443.
39. Li Z., Wang S., Wu Y., Zhong G., Chen D. Immunization with chlamydial plasmid protein pORF5 DNA vaccine induces protective immunity against genital chlamydial infection in mice. Sci. China Ser. C: Life Sci. 2008, 51:973-980.
40. Lyons A., Longfield J., Kuschner R., Straight T., Binn L., Seriwatana J., Reistetter R., Froh I.B., Craft D., McNabb K., Russell K., Metzgar D., Liss A., Sun X., Towie A., Sun W.A. Double-blind, placebo-controlled study of the safety and immunogenicity of live, oral type 4 and type 7 adenovirus vaccines in adults. Vaccine 2008, 26:2890-2898.
41. Ma Z., Lu F.X., Torten M., Miller C.J. The number and distribution of immune cells in the cervicovaginal mucosa remain constant throughout the menstrual cycle of rhesus macaques. Clin. Immunol. 2001, 100:240-249.
42. Marasco W., Sui J. The growth and potential of human antiviral monoclonal antibody therapeutics. Nat. Biotechnol. 2007, 25:1421-1434.
43. Mascola J.R., Stiegler G., VanCott T.C., Katinger H., Carpenter C.B., Hanson C.E., Beary H., Hayes D., Frankell S.S., Birx D.L., Lewis M.G. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat. Med. 2000, 6:207-210.
44. 649-684, a mucosal subunit HIV/AIDS vaccine candidate. Vaccine 2006, 24:5047-5055.
45. Mauck C.K., Callahan M.M., Baker J., Arbogast K., Veazy R., Stock R., Pan Z., Morrison C.S., Chen-Mok M., Archer D.F., Gabelnick H.L. The effect of one injection of Depo-Provera on the human vaginal epithelium and cervical ectopy. Contraception 1999, 60:15-24.
46. Mestecky J., Kutteh W.H., Jackson S. Mucosal immunity in the female genital tract: relevance to vaccination efforts against the human immunodeficiency virus. AIDS Res. Hum. Retroviruses 1994, 10:11-20.
47. Mestecky J., Moldoveanu Z., Russel M.W. Immunologic uniqueness of the genital tract: challenge for vaccine development. Am. J. Reprod. Immunol. 2005, 53:208-214.
48. Miller C.J., McChesney M., Moore P.F. Langerhans cells, macrophages and lymphocyte subsets in the cervix and vagina of rhesus macaques. Lab. Invest. 1992, 67:628-634.
49. Miller L., Patton D.L., Meier A., Thwin S.S., Hooton T.M., Eschenbach D.A. Depomedroxyprogesterone-induced hypoestrogenism and changes in vaginal flora an epithelium. Obstet. Gynecol. 2000, 96:431-439.
50. Nardelli-Haefliger D., Wirthner D., Schiller J.T., Lowy D.R., Hildesheim A., Ponci F., De Grandi P. Specific antibody levels at the cervix during the menstrual cycle of women vaccinated with human papillomavirus 16 virus-like particles. J. Natl. Cancer Inst. 2003, 95:1128-1137.
51. Nawar H.F., Greene C.J., Lee C.H., Mandell L.M., Hajishengallis G., Connell T.D. LT-IIc, a new member of the type II heat-labile enterotoxin family, exhibits potent immunomodulatory properties that are different from those induced by LT-IIa or LT-IIb. Vaccine 2011, 29:721-727.
52. Naz R.K. Effects of sperm-reactive antibodies present in human infertile sera on fertility of female rabbits. J. Reprod. Immunol. 1990, 18:161-177.
53. Naz R.K., Rajesh C. Passive immunization for immunocontraception: lessons learned from infectious diseases. Front. Biosci. 2004, 9:2457-2465.
54. Naz R.K., Chauhan S.C. Human sperm-specific peptide vaccine that causes long-term reversible contraception. Biol. Reprod. 2002, 67:674-680.
55. Naz R.K., Menge A.C. Antisperm antibodies: origin, regulation, and sperm reactivity in human infertility. Fertil. Steril. 1994, 61:1001-1013.
56. Naz R.K., Phillips T.M., Rosenblum B.B. Characterization of fertilization antigen 1 for the development of a contraceptive vaccine. Proc. Natl. Acad. Sci. U. S. A. 1986, 83:5713-5717.
57. Norvel M.K., Benrubi G.I., Thompson R.J. Investigation of microtrauma after sexual intercourse. J. Reprod. Med. 1984, 29:269-271.
58. Olivares-Zavaleta N., Whitmire W., Gardner D., Caldwell H.D. Immunization with the attenuated plasmidless Chlamydia trachomatis L2(25667R) strain provides partial protection in a murine model of female genitourinary tract infection. Vaccine 2010, 28:1454-1462.
59. Parr M.B., Parr E.L. Langerhans cells and T lymphocyte subsets in the murine vagina and cervix. Biol. Reprod. 1991, 44:491-498.
60. Parr T.B., Johnson T.A., Siberstein L.E., Kipps T.J. Anti-B cell autoantibodies encoded by VH 4-21 genes in human fetal spleen do not require in vivo somatic selection. Eur. J. Immunol. 1994, 24:2941-2949.
61. Pommerville J. Infectious diseases affecting the reproductive and urinary systems. Alcamo's Fundamentals of Microbiology: Body Systems 2010, 814-815. Jones and Bartlett Publishers, Sudbury, MA. J. Pommerville (Ed.).
62. Pudney J., Quayle A.J., Anderson D.J. Immunological microenvironments in the human vagina and cervix: mediators of cellular immunity are concentrated in the cervical transformation zone. Biol. Reprod. 2005, 73:1253-1263.
63. Rajini B., Zeng J., Suvas P.K., Dech H.M., Onami T.M. Both systemic and mucosal LCMV immunization generate robust viral-specific IgG in mucosal secretions, but elicit poor LCMV-specific IgA. Viral Immunol. 2010, 23:377-384.
64. Raska M., Belakova J., Horynova M., Krupka M., Novotny J., Sebestova M., Weigl E. Systemic and mucosal immunization with candida albicans hsp90 elicits hsp90-specific humoral response in vaginal mucosa which is further enhanced during experimental vaginal candidiasis. Med. Mycol. 2008, 46:411-420.
65. Rebello R., Green F.H.Y., Fox H. A study of the secretory immune system of the female genital tract. Br. J. Obstet. Gynaecol. 1975, 82:812-816.
66. Rodrigues M., Rowden M.G., Hackett J., Bakos I. Langerhans cells in the normal conjunctiva and peripheral cornea of selected species. Invest. Ophthalmol. Vis. Sci. 1981, 21:759-765.
67. Sacks E.H., Wieczorek R., Jokobiec F.A., Knowles I.I.D.M. Lymphocytic subpopulations in the normal human conjunctiva. A monoclonal antibody study. Ophthalmology 1986, 93:1276-1283.
68. Saling P.M., Waibel R. Mouse sperm antigens that participate in fertilization. III. Passive immunization with a single monoclonal antisperm antibody inhibits pregnancy and fertilization in vivo. Biol. Reprod. 1985, 33:537-544.
69. Santillan D.A., Andracki M.E., Hunter S.K. Protective immunization in mice against group B streptococci using encapsulated C5a peptidase. Am. J. Obstet. Gynecol. 2008, 198:114e1-114e6.
70. Schumacher M.J., Mitchell G.F. Inhibition of murine reaginic antibody responses by nasal immunotherapy with modified allergen. Int. Arch. Allergy Appl. Immunol. 1980, 62:383-388.
71. Seo K.Y., Han S.J., Cha H.R., Seo S.U., Song J.H., Chung S.H., Kweon M.N. Eye mucosa: an efficient vaccine delivery route for inducing protective immunity. J. Immunol. 2010, 185:3610-3619.
72. Shackett B.L., Greenblatt R.M. Immune responses to HIV in the female reproductive tract, immunologic parallels with the gastrointestinal tract, and research implications. Am. J. Reprod. Immunol. 2011, 65:230-241.
73. Song W., Condron S., Mocca B.T., Veit S.J., Hill D., Abbas A., Jerse A.E. Local and humoral immune responses against primary and repeat neisseria gonorrhoeae genital tract infections of 17β-estradiol-treated mice. Vaccine 2008, 26:5741-5751.
74. Staras S.A., Cook R.L., Clark D.B. Sexual partner characteristics and sexually transmitted diseases among adolescents and young adults. Sex. Transm. Dis. 2009, 36:232-238.
75. STD Statistics Worldwide. Available at: (accessed on 13.05.11). http://www.avert.org.stdstatisticsworldwide.htm/.
76. Sullivan D.A., Wira C.R. Hormonal regulation of immunoglobulins in the rat uterus: uterine response to multiple estradiol treatments. Endocrinology 1984, 114:650-658.
77. Sundling C., Schon K., Morner A., Forsell M.N.E., Wyatt R.T., Thorstensson R., Karlsson Hedestam G.B., Lycke N.Y. CTA-1DD adjuvant promotes strong immunity against human immunodeficiency virus type 1 envelope glycoproteins following mucosal immunization. J. Gen. Virol. 2008, 89:2954-2964.
78. Tengvall S., Lundqvist A., Eisenberg R.J., Cohen G.H., Harandi A.M. Mucosal administration of CpG oligodeoxynucleotide elicits strong CC and CXC chemokine responses in the vagina and serves as a potent Th1-tilting adjuvant for recombinant gD2 protein vaccination against genital herpes. J. Virol. 2006, 80:5283-5291.
79. Trussel J. Contraceptive failure in the United States. Contraception 2004, 70:89-96.
80. Valore E.V., Park C.H., Igreti S.L., Ganz T. Antimicrobial components of vaginal fluid. Am. J. Obstet. Gynecol. 2002, 187:561-568.
81. Vendetti S., Riccomi A., Negri D.R.M., Veglia F., Sciaraffia E., De Magistris M.T. Development of antigen-specific T cells in mediastinal lymph nodes after intranasal immunization. Methods 2009, 49:334-339.
82. Wei C., Liu J., Hou X., Yu L., Lee J., Kim C. Immunogenicity and protective efficacy of orally or intranasally administered recombinant lactobacillus casei expressing ETEC K99. Vaccine 2010, 28:4113-4118.
83. White H.D., Crassi K.M., Givan A.L., Stern J.E., Gonzalez J.L., Memoli V.A., Green W.R., Wira C.R. CD3+ CD8+ CTL activity within the female reproductive tract: influence of stage of the menstrual cycle and menopause. J. Immunol. 1997, 158:3017-3027.
84. WHO/63 News Release. Available at: (01.11.06). http://whqlibdoc.who.int/press_release/2006/PR_63.pdf.
85. Wira C.R., Patel M.V., Ghosh M., Mukura L., Fahey J.V. Innate immunity in the human female reproductive tract: endocrine regulation of endogenous antimicrobial protection against HIV and other sexually transmitted infections. Am. J. Reprod. Immunol. 2011, 65:196-211.
86. Woof J.M., Mestecky J. Mucosal immunoglobulins. Immunol. Rev. 2005, 206:64-82.
87. World POPClock Projection. US Census Bureau (online). Available at: (accessed on 12.09.11). http://www.census.gov/main/www/popclock.html/.
88. Wright P.F. Inductive/effector mechanisms for humoral immunity at mucosal sites. Am. J. Reprod. Immunol. 2011, 65:248-252.
89. Wright P.F., Kozlowski P.A., Rybczk G.K., Goepfert P., Staats H.F., VanCott T.C., Trabattoni D., Sannella E., Mestecky J. Detection of mucosal antibodies in HIV type-1 infected individuals. AIDS Res. Hum. Retroviruses 2002, 18:1291-1300.
90. Xin W., Li Y., Mo H., Roland K.L., Curtiss R. PsaA family fusion proteins delivered by attenuated Salmonella enteric servovar typhimurium extended and enhance protection against streptococcus pneumonia. Infect. Immun. 2009, 77:4518-4528.
91. Xue G., Yu L., Li S., Shen X. Intranasal immunization with GBS surface protein Sip and ScpB induces specific mucosal and systemic immune responses in mice. FEMS Immunol. Med. Microbiol. 2010, 58:202-210.
92. Yao X.Y., Yuan M.M., Li D.J. Molecular adjuvant C3d3 improved the anti-hCGβ humoral immune response in vaginal inoculation with live recombinant lactobacillus expressing hCGβ-C3d3 fusion protein. Vaccine 2007, 25:6129-6139.
93. Yeaman G.R., Guyre P.M., Fanger M.W., Collins J.E., White H.D., Rathbun W., Orndorff K.A., Gonzalez J., Stern J.E., Wira C.R. Unique CD8+ T cell-rich lymphoid aggregates in human uterine endometrium. J. Leukoc. Biol. 1997, 61:427-435.
94. Zhang P., Lewis J.P., Michalek S.M., Katz J. Role of CD80 and CD86 in host immune responses to the recombinant hemagglutinin domain of porphyromonas gingivalis gingipain and in the adjuvanticity of cholera toxin B and monophosphoryl lipid A. Vaccine 2007, 25:6201-6210.
95. Zhang X., Chentoufi A.A., Dasgupta G., Nesburn A.B., Wu M., Zhu X., Carpenter D., Wechsler S.L., You S., BenMohamed L. A genital tract peptide epitope vaccine targeting TLR-2 efficiently induces local and systemic CD8+ T cells and protects against herpes simplex virus type 2 challenge. Mucosal Immunol. 2009, 2:129-143.
96. Zhu D., Barniak V., Zhang Y., Green B., Zlotnick G. Intranasal immunization of mice with recombinant lapidated P2086 protein reduces nasal colonization of group B neisseria meningitides. Vaccine 2006, 24:5420-5425.